Behnke 2002.

Methods	Six‐week double‐blind, randomised multicentre study
Participants	Patients with ICD‐10 depression, with a score between 16 and 24 points on Hamilton Rating Scale for Depression (HDRS‐17). Age range: 18‐73 years Exclusion criteria: participation in a clinical study less than 4 weeks, pregnancy and lactation, insufficient contraception, suicide risk, dementia, or other severe intellectual impairment, chronic alcohol or drug abuse or dependence, severe cardiac, liver, kidney or respiratory insufficiency, neoplasia, Parkinson's or Alzheimer's disease, hypersensitivity to an ingredient of the Hypericum perforatum, febrile illness, anaemia, thyroid or parathyroid disease, pituitary insufficiency.
Interventions	Fluoxetine: 35 participants Hypericum: 35 participants Fluoxetine dose: 40 mg/day Hypericum dose: 300 mg/day
Outcomes	HDRS‐17, von Zerssen Depression Scale (VZD), Clinical Global Impression (CGI) Scale
Notes	Funding: by industry
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Randomised, no other information
Allocation concealment (selection bias)	Unclear risk	No information provided
Blinding (performance bias and detection bias) All outcomes	Unclear risk	Double blind, no further information
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Double blind, no further information
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Double blind, no further information
Incomplete outcome data (attrition bias) All outcomes	High risk	Number of dropouts reported, but reasons not specified. Endpoint scores reported without denominator
Selective reporting (reporting bias)	Unclear risk	Side effects not reported. Mean endpoint scores and standard deviation reported
Other bias	High risk	Last author's affiliation was PhytoPharm Consulting, Istitute for Phytopharmaceuticals, Berlin; probably this company produces Hypericum perforatum